

Nienke Biermasz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/391192/publications.pdf>

Version: 2024-02-01

261
papers

12,222
citations

25423

59
h-index

40945

97
g-index

273
all docs

273
docs citations

273
times ranked

9722
citing authors

#	ARTICLE	IF	CITATIONS
1	Unexpected concomitant pituitary adenoma and suprasellar meningioma: a case report and review of the literature. <i>British Journal of Neurosurgery</i> , 2023, 37, 677-681.	0.4	10
2	Low sclerostin levels after long-term remission of acromegaly. <i>Endocrine</i> , 2022, 75, 228-238.	1.1	2
3	Low prevalence of neuropathic-like pain symptoms in long-term controlled acromegaly. <i>Pituitary</i> , 2022, 25, 229-237.	1.6	3
4	Impact of patient-reported nasal symptoms on quality of life after endoscopic pituitary surgery: a prospective cohort study. <i>Pituitary</i> , 2022, 25, 308-320.	1.6	4
5	Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 102-111.	5.5	23
6	State of the Art of Patient-reported Outcomes in Acromegaly or GH Deficiency: A Systematic Review and Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1225-1238.	1.8	9
7	Long-term effects of glucocorticoid excess on the brain. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	1.2	23
8	Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery. <i>Pituitary</i> , 2022, 25, 587-601.	1.6	9
9	Clinical and radiographic assessment of peripheral joints in controlled acromegaly. <i>Pituitary</i> , 2022, 25, 622-635.	1.6	5
10	Testosterone in men with hypogonadism and transgender males: a systematic review comparing three different preparations. <i>Endocrine Connections</i> , 2022, 11, .	0.8	3
11	Progression of acromegalic arthropathy in long-term controlled acromegaly patients: 9 years of longitudinal follow-up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 188-200.	1.8	17
12	Improvement in Symptoms and Health-Related Quality of Life in Acromegaly Patients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 577-587.	1.8	19
13	Sleep characteristics across the lifespan in 1.1 million people from the Netherlands, United Kingdom and United States: a systematic review and meta-analysis. <i>Nature Human Behaviour</i> , 2021, 5, 113-122.	6.2	193
14	Pre-operative serum inflammation-based scores in patients with pituitary adenomas. <i>Pituitary</i> , 2021, 24, 334-350.	1.6	21
15	Healthcare utilization and costs among prolactinoma patients: a cross-sectional study and analysis of determinants. <i>Pituitary</i> , 2021, 24, 79-95.	1.6	5
16	Chiasmal herniation following treatment of pituitary macroadenoma. <i>Pituitary</i> , 2021, 24, 68-78.	1.6	3
17	Osteoporosis and arthropathy in functioning pituitary tumors. , 2021, , 617-637.		0
18	Conditioning cortisol in healthy young women – A randomized controlled trial. <i>Psychoneuroendocrinology</i> , 2021, 124, 105081.	1.3	5

#	ARTICLE	IF	CITATIONS
19	Central serous chorioretinopathy in active endogenous Cushing's syndrome. <i>Scientific Reports</i> , 2021, 11, 2748.	1.6	10
20	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa205.	0.1	31
21	Outcome Squares Integrating Efficacy and Safety, as Applied to Functioning Pituitary Adenoma Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3300-e3311.	1.8	7
22	Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands. <i>Frontiers in Endocrinology</i> , 2021, 12, 627711.	1.5	18
23	Investigating the relationships between unfavourable habitual sleep and metabolomic traits: evidence from multi-cohort multivariable regression and Mendelian randomization analyses. <i>BMC Medicine</i> , 2021, 19, 69.	2.3	14
24	Multi-ancestry genome-wide gene-sleep interactions identify novel loci for blood pressure. <i>Molecular Psychiatry</i> , 2021, 26, 6293-6304.	4.1	13
25	Serum Inflammation-based Scores in Endocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3796-e3819.	1.8	19
26	A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands. <i>Journal of the Endocrine Society</i> , 2021, 5, A517-A517.	0.1	3
27	Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy. <i>Journal of the Endocrine Society</i> , 2021, 5, A518-A519.	0.1	2
28	Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results From the MPOWERED Trial. <i>Journal of the Endocrine Society</i> , 2021, 5, A522-A523.	0.1	0
29	Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial. <i>Journal of the Endocrine Society</i> , 2021, 5, A520-A521.	0.1	2
30	Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly. <i>Journal of the Endocrine Society</i> , 2021, 5, A527-A528.	0.1	1
31	A physiological glucocorticoid rhythm is an important regulator of brown adipose tissue function. <i>Molecular Metabolism</i> , 2021, 47, 101179.	3.0	12
32	Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results. <i>Pituitary</i> , 2021, 24, 943-953.	1.6	11
33	Clinical Unmet Needs in the Treatment of Adrenal Crisis: Importance of the Patient's Perspective. <i>Frontiers in Endocrinology</i> , 2021, 12, 701365.	1.5	8
34	Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature. <i>European Journal of Endocrinology</i> , 2021, 185, 99-108.	1.9	8
35	The PRolaCT studies—a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma. <i>Trials</i> , 2021, 22, 653.	0.7	7
36	Postoperative diabetes insipidus: how to define and grade this complication?. <i>Pituitary</i> , 2021, 24, 284-291.	1.6	50

#	ARTICLE	IF	CITATIONS
37	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 847-875.	5.5	315
38	The DEXA-CORT trial: study protocol of a randomised placebo-controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasone. <i>BMJ Open</i> , 2021, 11, e054405.	0.8	3
39	Unmet needs and recommendations to improve meningioma care through patient, partner, and health care provider input: a mixed-method study. <i>Neuro-Oncology Practice</i> , 2020, 7, 239-248.	1.0	6
40	Opioids and Their Endocrine Effects: A Systematic Review and Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1020-1029.	1.8	66
41	Early postoperative HPA-axis testing after pituitary tumor surgery: reliability and safety of basal cortisol and CRH test. <i>Endocrine</i> , 2020, 67, 161-171.	1.1	14
42	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e937-e946.	1.8	207
43	Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e32-e41.	1.8	78
44	IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e70-e84.	1.8	22
45	Hair cortisol concentrations in chronic central serous chorioretinopathy. <i>Acta Ophthalmologica</i> , 2020, 98, 390-395.	0.6	5
46	Disruption of circadian rhythm by alternating light-dark cycles aggravates atherosclerosis development in APOE*3-Leiden.CETP mice. <i>Journal of Pineal Research</i> , 2020, 68, e12614.	3.4	45
47	The tale in evolution: clarity, consistency and consultation, not contradiction and confusion. <i>Pituitary</i> , 2020, 23, 476-477.	1.6	18
48	Continuous Light Does Not Affect Atherosclerosis in APOE*3-Leiden.CETP Mice. <i>Journal of Biological Rhythms</i> , 2020, 35, 598-611.	1.4	4
49	SF-12 or SF-36 in pituitary disease? Toward concise and comprehensive patient-reported outcomes measurements. <i>Endocrine</i> , 2020, 70, 123-133.	1.1	10
50	Endoscopic Surgery for Pituitary Tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 487-503.	1.2	17
51	The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a ⁶⁸ Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size. <i>BMJ Open</i> , 2020, 10, e038250.	0.8	2
52	Multidisciplinary management of acromegaly: A consensus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 667-678.	2.6	183
53	Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3785-e3797.	1.8	54
54	Effect of anthelmintic treatment on serum free IGF-1 and IGFBP-3: a cluster-randomized-controlled trial in Indonesia. <i>Scientific Reports</i> , 2020, 10, 19023.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Feasibility, safety, and outcomes of a stratified fast-track care trajectory in pituitary surgery. <i>Endocrine</i> , 2020, 69, 175-187.	1.1	18
56	Quality of care evaluation in non-functioning pituitary adenoma with chiasm compression: visual outcomes and timing of intervention clinical recommendations based on a systematic literature review and cohort study. <i>Pituitary</i> , 2020, 23, 417-429.	1.6	7
57	Response to Letter to the Editor: "Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3040-e3041.	1.8	4
58	Response to Letter to the Editor: "IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2315-e2316.	1.8	0
59	Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell tumour of bone. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 348.	5.5	1
60	⁶⁸ Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 4.	0.6	5
61	An overview of clinical activities in Endo-ERN: the need for alignment of future network criteria. <i>European Journal of Endocrinology</i> , 2020, 183, 141-148.	1.9	9
62	MON-LB55 Biochemical Control of Most Patients Reverting to Injectable Long-Acting Somatostatin Receptor Ligands Is Achieved After One Dose: Results From the Phase 3, Randomized, Double Blind, Placebo-Controlled Optimal Study. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
63	MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
64	MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
65	The burden of disease for pituitary patients. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101309.	2.2	26
66	Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration. <i>Nature Communications</i> , 2019, 10, 5121.	5.8	62
67	Disruption Of The Biological Clock Affects Immune Homeostasis And Aggravates Atherosclerosis Development. <i>Atherosclerosis</i> , 2019, 287, e16.	0.4	0
68	A tale of pituitary adenomas: to NET or not to NET. <i>Pituitary</i> , 2019, 22, 569-573.	1.6	60
69	Improvement but no normalization of quality of life and cognitive functioning after treatment for Cushing's syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5325-5337.	1.8	27
70	Sex Differences in Presentation but Not in Outcome for ACTH-Dependent Cushing's Syndrome. <i>Frontiers in Endocrinology</i> , 2019, 10, 580.	1.5	13
71	A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 883-891.	1.8	13
72	Time-restricted feeding improves adaptation to chronically alternating light-dark cycles. <i>Scientific Reports</i> , 2019, 9, 7874.	1.6	17

#	ARTICLE	IF	CITATIONS
73	The Association between Habitual Sleep Duration and Sleep Quality with Glycemic Traits: Assessment by Cross-Sectional and Mendelian Randomization Analyses. <i>Journal of Clinical Medicine</i> , 2019, 8, 682.	1.0	14
74	Healthcare utilization and costs among patients with non-functioning pituitary adenomas. <i>Endocrine</i> , 2019, 64, 330-340.	1.1	9
75	Microscopic versus endoscopic transsphenoidal surgery in the Leiden cohort treated for Cushing's disease: surgical outcome, mortality, and complications. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 64.	1.2	24
76	Maladaptive personality traits, psychological morbidity and coping strategies in chronic central serous chorioretinopathy. <i>Acta Ophthalmologica</i> , 2019, 97, e572-e579.	0.6	18
77	Associations of sleep duration and quality with serum and hepatic lipids: The Netherlands Epidemiology of Obesity Study. <i>Journal of Sleep Research</i> , 2019, 28, e12776.	1.7	14
78	The partner's perspective of the impact of pituitary disease: Looking beyond the patient. <i>Journal of Health Psychology</i> , 2019, 24, 1687-1697.	1.3	19
79	The incidence of adrenal crisis in the postoperative period of HPA axis insufficiency after surgical treatment for Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2019, 181, 201-210.	1.9	14
80	Toward Value Based Health Care in pituitary surgery: application of a comprehensive outcome set in perioperative care. <i>European Journal of Endocrinology</i> , 2019, 181, 375-387.	1.9	19
81	IGF-1 and IGF-1 SDS "fit for purpose?". <i>European Journal of Endocrinology</i> , 2019, 181, L1-L4.	1.9	2
82	Mapping AcroQoL scores to EQ-5D to obtain utility values for patients with acromegaly. <i>Journal of Medical Economics</i> , 2018, 21, 382-389.	1.0	12
83	How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review. <i>Pituitary</i> , 2018, 21, 208-216.	1.6	29
84	How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. <i>Pituitary</i> , 2018, 21, 310-322.	1.6	19
85	A Diurnal Rhythm in Brown Adipose Tissue Causes Rapid Clearance and Combustion of Plasma Lipids at Wakening. <i>Cell Reports</i> , 2018, 22, 3521-3533.	2.9	68
86	Preoperative risk factors for postoperative complications in endoscopic pituitary surgery: a systematic review. <i>Pituitary</i> , 2018, 21, 84-97.	1.6	84
87	Decrease in scale invariance of activity fluctuations with aging and in patients with suprasellar tumors. <i>Chronobiology International</i> , 2018, 35, 368-377.	0.9	5
88	Disruption of the biological clock aggravates atherosclerosis. <i>Atherosclerosis</i> , 2018, 275, e13-e14.	0.4	0
89	Work disability and its determinants in patients with pituitary tumor-related disease. <i>Pituitary</i> , 2018, 21, 593-604.	1.6	31
90	Habitual Sleep Measures are Associated with Overall Body Fat, and not Specifically with Visceral Fat, in Men and Women. <i>Obesity</i> , 2018, 26, 1651-1658.	1.5	11

#	ARTICLE	IF	CITATIONS
91	Associations between measures of sleep with serum and hepatic lipid profile: The Netherlands epidemiology of obesity study. <i>Atherosclerosis</i> , 2018, 275, e77.	0.4	0
92	Endoscopic vs. microscopic transsphenoidal surgery for Cushing's disease: a systematic review and meta-analysis. <i>Pituitary</i> , 2018, 21, 524-534.	1.6	71
93	Effectiveness of medical treatment for Cushing's syndrome: a systematic review and meta-analysis. <i>Pituitary</i> , 2018, 21, 631-641.	1.6	61
94	Cushing's Syndrome and Hypothalamic-Pituitary-Adrenal Axis Hyperactivity in Chronic Central Serous Chorioretinopathy. <i>Frontiers in Endocrinology</i> , 2018, 9, 39.	1.5	22
95	New medical therapies on the horizon: oral octreotide. <i>Pituitary</i> , 2017, 20, 149-153.	1.6	27
96	Bone material strength index as measured by impact microindentation is altered in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2017, 176, 339-347.	1.9	51
97	Understanding and predicting fracture risk in acromegaly. <i>Endocrine</i> , 2017, 55, 662-663.	1.1	2
98	Familial longevity is characterized by high circadian rhythmicity of serum cholesterol in healthy elderly individuals. <i>Aging Cell</i> , 2017, 16, 237-243.	3.0	19
99	Enhanced self-efficacy after a self-management programme in pituitary disease: a randomized controlled trial. <i>European Journal of Endocrinology</i> , 2017, 177, 59-72.	1.9	38
100	Acromegalic arthropathy in various stages of the disease: an MRI study. <i>European Journal of Endocrinology</i> , 2017, 176, 779-790.	1.9	18
101	Health-related quality of life of cranial WHO grade I meningioma patients: are current questionnaires relevant?. <i>Acta Neurochirurgica</i> , 2017, 159, 2149-2159.	0.9	27
102	Mapping Acroqol Scores to EQ-5D to Obtain Utility Values for Patients with Acromegaly. <i>Value in Health</i> , 2017, 20, A484.	0.1	0
103	Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters. <i>Frontiers in Endocrinology</i> , 2017, 8, 40.	1.5	63
104	Poor sleep quality and later sleep timing are risk factors for osteopenia and sarcopenia in middle-aged men and women: The NEO study. <i>PLoS ONE</i> , 2017, 12, e0176685.	1.1	74
105	Pituitary Adenoma Apoplexy in an Adolescent: A Case Report and Review of the Literature. <i>JCRPE Journal of Clinical Research in Pediatric Endocrinology</i> , 2017, 9, 265-273.	0.4	3
106	Chronic Central Serous Chorioretinopathy as a Presenting Symptom of Cushing Syndrome. <i>European Journal of Ophthalmology</i> , 2016, 26, 442-448.	0.7	27
107	The Role of the Suprachiasmatic Nucleus in Cardiac Autonomic Control during Sleep. <i>PLoS ONE</i> , 2016, 11, e0152390.	1.1	3
108	Pituitary Hormone Secretion Profiles in IGSF1 Deficiency Syndrome. <i>Neuroendocrinology</i> , 2016, 103, 408-416.	1.2	22

#	ARTICLE	IF	CITATIONS
109	Optimizing Blood Sampling Protocols in Patients With Acromegaly for the Estimation of Growth Hormone Secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2675-2682.	1.8	8
110	Mutations in <i>TBL1X</i> Are Associated With Central Hypothyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4564-4573.	1.8	73
111	Quality of life in patients with adrenal insufficiency correlates stronger with hydrocortisone dosage, than with long-term systemic cortisol levels. <i>Psychoneuroendocrinology</i> , 2016, 72, 80-86.	1.3	15
112	Mild deficits in attentional control in patients with the <i>IGSF1</i> deficiency syndrome. <i>Clinical Endocrinology</i> , 2016, 84, 896-903.	1.2	20
113	Bone and Joint Disorders in Acromegaly. <i>Neuroendocrinology</i> , 2016, 103, 86-95.	1.2	60
114	Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. <i>European Journal of Endocrinology</i> , 2016, 174, 651-662.	1.9	40
115	The development and validation of the Leiden Bother and Needs Questionnaire for patients with pituitary disease: the LBNQ-Pituitary. <i>Pituitary</i> , 2016, 19, 293-302.	1.6	30
116	Effects of discontinuation of growth hormone replacement in adult GH-deficient patients: a cohort study and a systematic review of the literature. <i>European Journal of Endocrinology</i> , 2016, 174, 705-716.	1.9	9
117	Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. <i>European Journal of Endocrinology</i> , 2016, 174, 355-362.	1.9	56
118	A single night of sleep curtailment increases plasma acylcarnitines: Novel insights in the relationship between sleep and insulin resistance. <i>Archives of Biochemistry and Biophysics</i> , 2016, 589, 145-151.	1.4	45
119	Mild cognitive deficits in patients with primary adrenal insufficiency. <i>Psychoneuroendocrinology</i> , 2016, 63, 170-177.	1.3	24
120	Mild cognitive deficits in patients on stable treatment for primary adrenal insufficiency. <i>Psychoneuroendocrinology</i> , 2015, 61, 46.	1.3	2
121	Time- and state-dependent analysis of autonomic control in narcolepsy: higher heart rate with normal heart rate variability independent of sleep fragmentation. <i>Journal of Sleep Research</i> , 2015, 24, 206-214.	1.7	27
122	Persistent negative illness perceptions despite long-term biochemical control of acromegaly: novel application of the drawing test. <i>European Journal of Endocrinology</i> , 2015, 172, 583-593.	1.9	21
123	MECHANISMS IN ENDOCRINOLOGY: Cushing's syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. <i>European Journal of Endocrinology</i> , 2015, 173, R1-R14.	1.9	141
124	Increased Hair Cortisol Concentrations and BMI in Patients With Pituitary-Adrenal Disease on Hydrocortisone Replacement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2456-2462.	1.8	21
125	Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. <i>Pituitary</i> , 2015, 18, 752-776.	1.6	95
126	Resting-State Functional Connectivity in Patients with Long-Term Remission of Cushing's Disease. <i>Neuropsychopharmacology</i> , 2015, 40, 1888-1898.	2.8	44

#	ARTICLE	IF	CITATIONS
127	IGSF1 variants in boys with familial delayed puberty. <i>European Journal of Pediatrics</i> , 2015, 174, 687-692.	1.3	19
128	Is IGSF1 involved in human pituitary tumor formation?. <i>Endocrine-Related Cancer</i> , 2015, 22, 47-54.	1.6	16
129	Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1699-1708.	1.8	144
130	Total score or subscales in scoring the acromegaly quality of life questionnaire: using novel confirmatory methods to compare scoring options. <i>European Journal of Endocrinology</i> , 2015, 173, 37-42.	1.9	5
131	Prolonged daily light exposure increases body fat mass through attenuation of brown adipose tissue activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 6748-6753.	3.3	115
132	Outcome of complications in acromegaly patients after long-term disease remission. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 499-510.	1.2	4
133	More concerns and stronger beliefs about the necessity of medication in patients with acromegaly are associated with negative illness perceptions and impairment in quality of life. <i>Growth Hormone and IGF Research</i> , 2015, 25, 219-226.	0.5	19
134	Spatial and temporal expression of immunoglobulin superfamily member 1 in the rat. <i>Journal of Endocrinology</i> , 2015, 226, 181-191.	1.2	28
135	Altered neural processing of emotional faces in remitted Cushing's disease. <i>Psychoneuroendocrinology</i> , 2015, 59, 134-146.	1.3	40
136	Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL. <i>Pituitary</i> , 2015, 18, 86-100.	1.6	51
137	High Prevalence of Metabolic Syndrome Features in Patients Previously Treated for Nonfunctioning Pituitary Macroadenoma. <i>PLoS ONE</i> , 2014, 9, e90602.	1.1	15
138	Determinants of Altered Sleep-Wake Rhythmicity in Patients Treated for Nonfunctioning Pituitary Macroadenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4497-4505.	1.8	23
139	Hormone Secretion by Pituitary Adenomas Is Characterized by Increased Disorderliness and Spikiness but More Regular Pulsing. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3836-3844.	1.8	9
140	Mortality in acromegaly reduced with multimodal therapy. <i>Nature Reviews Endocrinology</i> , 2014, 10, 708-710.	4.3	6
141	Effects of up to 15 years of recombinant human <sc>GH</sc> (rh<sc>GH</sc>) replacement on bone metabolism in adults with Growth Hormone Deficiency (<sc>GHD</sc>): The Leiden Cohort Study. <i>Clinical Endocrinology</i> , 2014, 81, 727-735.	1.2	29
142	Pituitary dysfunction in adult patients after cranial irradiation for head and nasopharyngeal tumours. <i>Radiotherapy and Oncology</i> , 2014, 113, 102-107.	0.3	29
143	A long-term follow-up study of eighteen patients with thyrotrophin-secreting pituitary adenomas. <i>Clinical Endocrinology</i> , 2014, 80, 395-402.	1.2	52
144	Patients With Adrenal Insufficiency Hate Their Medication: Concerns and Stronger Beliefs About the Necessity of Hydrocortisone Intake Are Associated With More Negative Illness Perceptions. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3668-3676.	1.8	27

#	ARTICLE	IF	CITATIONS
145	Alterations in diurnal rhythmicity in patients treated for nonfunctioning pituitary macroadenoma: a controlled study and literature review. <i>European Journal of Endocrinology</i> , 2014, 171, 217-228.	1.9	33
146	Abnormal metabolic phenotype in middle-aged GH-deficient adults despite long-term recombinant human GH replacement. <i>European Journal of Endocrinology</i> , 2014, 170, 263-272.	1.9	7
147	Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study. <i>Pituitary</i> , 2014, 17, 44-52.	1.6	25
148	Illness perceptions, risk perception and worry in SDH mutation carriers. <i>Familial Cancer</i> , 2014, 13, 83-91.	0.9	1
149	Thyrotropin Secretion in Healthy Subjects Is Robust and Independent of Age and Gender, and Only Weakly Dependent on Body Mass Index. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 570-578.	1.8	28
150	Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency: cross-sectional study and review of the literature. <i>European Journal of Endocrinology</i> , 2014, 171, 171-182.	1.9	61
151	Relationship between the functional exon 3 deleted growth hormone receptor polymorphism and symptomatic osteoarthritis in women. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 433-436.	0.5	5
152	Widespread reductions of white matter integrity in patients with long-term remission of Cushing's disease. <i>NeuroImage: Clinical</i> , 2014, 4, 659-667.	1.4	76
153	The IGSF1 Deficiency Syndrome: Characteristics of Male and Female Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4942-4952.	1.8	81
154	The Suprachiasmatic Nucleus Controls Circadian Energy Metabolism and Hepatic Insulin Sensitivity. <i>Diabetes</i> , 2013, 62, 1102-1108.	0.3	152
155	Two phenotypes of arthropathy in long-term controlled acromegaly? A comparison between patients with and without joint space narrowing (JSN). <i>Growth Hormone and IGF Research</i> , 2013, 23, 159-164.	0.5	14
156	Smaller grey matter volumes in the anterior cingulate cortex and greater cerebellar volumes in patients with long-term remission of Cushing's disease: a case-control study. <i>European Journal of Endocrinology</i> , 2013, 169, 811-819.	1.9	84
157	Metabolic Profile in Growth Hormone-Deficient (GHD) Adults after Long-Term Recombinant Human Growth Hormone (rhGH) Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 352-361.	1.8	57
158	Therapy of Endocrine disease: Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. <i>European Journal of Endocrinology</i> , 2013, 169, R1-R14.	1.9	74
159	Detrimental effects of constant light exposure and high-fat diet on circadian energy metabolism and insulin sensitivity. <i>FASEB Journal</i> , 2013, 27, 1721-1732.	0.2	213
160	Glucocorticoid excess induces long-lasting changes in body composition in male C57Bl/6J mice only with high-fat diet. <i>Physiological Reports</i> , 2013, 1, e00103.	0.7	12
161	IGSF1 deficiency syndrome. <i>Rare Diseases (Austin, Tex)</i> , 2013, 1, e24883.	1.8	29
162	Both Transient and Continuous Corticosterone Excess Inhibit Atherosclerotic Plaque Formation in APOE*3-Leiden.CETP Mice. <i>PLoS ONE</i> , 2013, 8, e63882.	1.1	14

#	ARTICLE	IF	CITATIONS
163	Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2012, 166, 27-34.	1.9	62
164	Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. <i>European Journal of Endocrinology</i> , 2012, 167, 235-244.	1.9	46
165	Automated image analysis of hand radiographs reveals widened joint spaces in patients with long-term control of acromegaly: relation to disease activity and symptoms. <i>European Journal of Endocrinology</i> , 2012, 166, 407-413.	1.9	19
166	The use of an early postoperative CRH test to assess adrenal function after transsphenoidal surgery for pituitary adenomas. <i>Pituitary</i> , 2012, 15, 436-444.	1.6	12
167	Treatment of nonfunctioning pituitary adenomas: What were the contributions of the last 10years? A critical view. <i>Annales D'Endocrinologie</i> , 2012, 73, 111-116.	0.6	20
168	Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. <i>Nature Genetics</i> , 2012, 44, 1375-1381.	9.4	169
169	Drawings Reflect a New Dimension of the Psychological Impact of Long-Term Remission of Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3123-3131.	1.8	32
170	The effects of high fat diet on the basal activity of the hypothalamusâ€“pituitaryâ€“adrenal axis in mice. <i>Journal of Endocrinology</i> , 2012, 214, 191-197.	1.2	48
171	Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2â€“year followâ€“up study. <i>Clinical Endocrinology</i> , 2012, 77, 99-105.	1.2	54
172	Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. <i>Pituitary</i> , 2012, 15, 71-83.	1.6	274
173	Low Incidence of Adrenal Insufficiency after Transsphenoidal Surgery in Patients with Acromegaly: A Long-Term Follow-Up Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1163-E1170.	1.8	17
174	Patients Previously Treated for Nonfunctioning Pituitary Macroadenomas Have Disturbed Sleep Characteristics, Circadian Movement Rhythm, and Subjective Sleep Quality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1524-1532.	1.8	50
175	Pituitary Dysfunction in Adult Patients after Cranial Radiotherapy: Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2330-2340.	1.8	126
176	Meta-Analysis and Dose-Response Metaregression: Circulating Insulin-Like Growth Factor I (IGF-I) and Mortality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2912-2920.	1.8	131
177	Affected Illness Perceptions and the Association with Impaired Quality of Life in Patients with Long-Term Remission of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3550-3558.	1.8	69
178	Stimulatory Effect of Insulin on Glucose Uptake by Muscle Involves the Central Nervous System in Insulin-Sensitive Mice. <i>Diabetes</i> , 2011, 60, 3132-3140.	0.3	22
179	Negative illness perceptions are associated with impaired quality of life in patients after long-term remission of Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2011, 165, 527-535.	1.9	77
180	Low prevalence of hypopituitarism after traumatic brain injury: a multicenter study. <i>European Journal of Endocrinology</i> , 2011, 165, 225-231.	1.9	59

#	ARTICLE	IF	CITATIONS
181	Effects of High Fat Diet on the Basal Activity of the Hypothalamus-Pituitary-Adrenal Axis in Mice: A Systematic Review. <i>Hormone and Metabolic Research</i> , 2011, 43, 899-906.	0.7	23
182	Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 320-325.	0.5	43
183	GH replacement therapy in elderly GH-deficient patients: a systematic review. <i>European Journal of Endocrinology</i> , 2011, 164, 657-665.	1.9	50
184	Coping Strategies in Patients after Treatment for Functioning or Nonfunctioning Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 964-971.	1.8	67
185	High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. <i>European Journal of Endocrinology</i> , 2011, 164, 475-483.	1.9	125
186	A Single Night of Partial Sleep Deprivation Induces Insulin Resistance in Multiple Metabolic Pathways in Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2963-2968.	1.8	301
187	Partial Sleep Restriction Decreases Insulin Sensitivity in Type 1 Diabetes. <i>Diabetes Care</i> , 2010, 33, 1573-1577.	4.3	126
188	Hypopituitarism following traumatic brain injury: prevalence is affected by the use of different dynamic tests and different normal values. <i>European Journal of Endocrinology</i> , 2010, 162, 11-18.	1.9	112
189	Increased Prevalence of Psychopathology and Maladaptive Personality Traits after Long-Term Cure of Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E129-E141.	1.8	121
190	Increased Psychopathology and Maladaptive Personality Traits, But Normal Cognitive Functioning, In Patients after Long-Term Cure of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E392-E402.	1.8	63
191	Acromegaly Is Associated with an Increased Prevalence of Colonic Diverticula: A Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2073-2079.	1.8	46
192	Subtle Cognitive Impairments in Patients with Long-Term Cure of Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2699-2714.	1.8	140
193	Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. <i>Growth Hormone and IGF Research</i> , 2010, 20, 226-233.	0.5	54
194	New consensus in acromegaly: criteria for cure and control. <i>Nature Reviews Endocrinology</i> , 2010, 6, 480-481.	4.3	5
195	Lanreotide Autogel [®] in the Treatment of Acromegaly. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2150.	0.1	0
196	Cost-effectiveness of lanreotide Autogel [®] in treatment algorithms of acromegaly. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 223-234.	0.7	27
197	The Exon-3 Deleted Growth Hormone Receptor Polymorphism Predisposes to Long-Term Complications of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4671-4678.	1.8	33
198	Diminished and irregular TSH secretion with delayed acrophase in patients with Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2009, 161, 695-703.	1.9	33

#	ARTICLE	IF	CITATIONS
199	Pretreatment Insulin-Like Growth Factor-I Concentrations Predict Radiographic Osteoarthritis in Acromegalic Patients with Long-Term Cured Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2374-2379.	1.8	32
200	Diminished and Irregular Thyrotropin Secretion with Preserved Diurnal Rhythm in Patients with Active Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1945-1950.	1.8	26
201	Impact of the Exon 3-Deleted Growth Hormone (GH) Receptor Polymorphism on Baseline Height and the Growth Response to Recombinant Human GH Therapy in GH-Deficient (GHD) and Non-GHD Children with Short Stature: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3721-3730.	1.8	90
202	High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a case-control study. <i>European Journal of Endocrinology</i> , 2009, 160, 357-365.	1.9	70
203	Pituitary-hormone secretion by thyrotropinomas. <i>Pituitary</i> , 2009, 12, 200-210.	1.6	14
204	Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly. <i>Pituitary</i> , 2009, 12, 339-346.	1.6	39
205	Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly. <i>Clinical Endocrinology</i> , 2008, 69, 123-128.	1.2	65
206	Patients cured from craniopharyngioma or nonfunctioning pituitary macroadenoma (NFMA) suffer similarly from increased daytime somnolence despite normal sleep patterns compared to healthy controls. <i>Clinical Endocrinology</i> , 2008, 69, 769-774.	1.2	33
207	Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. <i>Clinical Endocrinology</i> , 2008, 69, 775-784.	1.2	148
208	The role of pegvisomant in the treatment of acromegaly. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 691-704.	1.4	9
209	Mortality in Acromegaly: A Metaanalysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 61-67.	1.8	464
210	Influence of the d3-Growth Hormone (GH) Receptor Isoform on Short-Term and Long-Term Treatment Response to GH Replacement in GH-Deficient Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2828-2834.	1.8	49
211	Increased aortic root diameters in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2008, 159, 97-103.	1.9	33
212	Therapeutic options in the management of acromegaly: focus on lanreotide Autogel®. <i>Biologics: Targets and Therapy</i> , 2008, 2, 463.	3.0	16
213	Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism. <i>European Journal of Endocrinology</i> , 2007, 157, 709-716.	1.9	15
214	Mortality in Patients Treated for Cushing's Disease Is Increased, Compared with Patients Treated for Nonfunctioning Pituitary Macroadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 976-981.	1.8	201
215	The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. <i>European Journal of Endocrinology</i> , 2007, 156, 455-462.	1.9	80
216	Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. <i>Pituitary</i> , 2007, 10, 237-249.	1.6	50

#	ARTICLE	IF	CITATIONS
217	Role of radiotherapy in the management of acromegaly. <i>Expert Review of Endocrinology and Metabolism</i> , 2006, 1, 449-460.	1.2	10
218	Efficacy of needle-free administration of recombinant human growth hormone in adults with growth hormone deficiency. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 451-455.	1.1	9
219	Quality of Life Is Decreased after Treatment for Nonfunctioning Pituitary Macroadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3364-3369.	1.8	111
220	GH deficiency in patients irradiated for acromegaly: significance of GH stimulatory tests in relation to the 24 h GH secretion. <i>European Journal of Endocrinology</i> , 2006, 154, 851-858.	1.9	20
221	Quality of life in treated adult craniopharyngioma patients. <i>European Journal of Endocrinology</i> , 2006, 154, 483-489.	1.9	103
222	Survival and Death Causes in Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 313-319.	1.8	248
223	Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. <i>European Journal of Endocrinology</i> , 2006, 155, 701-708.	1.9	43
224	Nanomedicines in the treatment of acromegaly: focus on pegvisomant. <i>International Journal of Nanomedicine</i> , 2006, 1, 385-398.	3.3	21
225	High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. <i>Clinical Endocrinology</i> , 2005, 62, 197-204.	1.2	182
226	Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly. <i>European Journal of Endocrinology</i> , 2005, 152, 53-60.	1.9	23
227	Effects of Dehydroepiandrosterone, Superimposed on Growth Hormone Substitution, on Quality of Life and Insulin-Like Growth Factor I in Patients with Secondary Adrenal Insufficiency: A Randomized, Placebo-Controlled, Cross-Over Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3295-3303.	1.8	61
228	Morbidity after Long-Term Remission for Acromegaly: Persisting Joint-Related Complaints Cause Reduced Quality of Life. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2731-2739.	1.8	182
229	Treatment strategies for acromegaly. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 875-890.	1.0	12
230	Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly. <i>European Journal of Endocrinology</i> , 2005, 153, 231-238.	1.9	24
231	Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. <i>Growth Hormone and IGF Research</i> , 2005, 15, 200-206.	0.5	32
232	Pharmacologic Therapies for Acromegaly. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2005, 4, 43-53.	1.8	24
233	Quality of Life in Patients after Long-Term Biochemical Cure of Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3279-3286.	1.8	225
234	Current pharmacotherapy for acromegaly: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2393-2405.	0.9	24

#	ARTICLE	IF	CITATIONS
235	Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 286, E25-E30.	1.8	41
236	Determinants of Survival in Treated Acromegaly in a Single Center: Predictive Value of Serial Insulin-Like Growth Factor I Measurements. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2789-2796.	1.8	188
237	Pituitary Magnetic Resonance Imaging Is Not Required in the Postoperative Follow-Up of Acromegalic Patients with Long-Term Biochemical Cure after Transsphenoidal Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4320-4324.	1.8	27
238	Decreased Quality of Life in Patients with Acromegaly Despite Long-Term Cure of Growth Hormone Excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5369-5376.	1.8	213
239	Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. <i>European Journal of Endocrinology</i> , 2004, 150, 489-495.	1.9	65
240	Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. <i>Clinical Endocrinology</i> , 2004, 60, 568-575.	1.2	49
241	Six-months of recombinant human GH therapy in patients with ischemic cardiac failure. <i>International Journal of Cardiovascular Imaging</i> , 2004, 20, 53-60.	0.7	8
242	Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. <i>Clinical Endocrinology</i> , 2003, 58, 288-295.	1.2	42
243	Long-Term Predictive Value of Postsurgical Cortisol Concentrations for Cure and Risk of Recurrence in Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5858-5864.	1.8	161
244	Physiological control of pituitary hormone secretory-burst mass, frequency, and waveform: a statistical formulation and analysis. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2003, 285, R664-R673.	0.9	80
245	Pulsatile, nyctohemeral and entropic characteristics of GH secretion in adult GH-deficient patients: selectively decreased pulsatile release and increased secretory disorderliness with preservation of diurnal timing and gender distinctions. <i>Clinical Endocrinology</i> , 2002, 56, 79-87.	1.2	19
246	Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly. <i>Clinical Endocrinology</i> , 2002, 56, 313-319.	1.2	21
247	Six Months of Recombinant Human GH Therapy in Patients with Ischemic Cardiac Failure Does Not Influence Left Ventricular Function and Mass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4638-4643.	1.8	42
248	Growth Hormone (GH) Secretion in Patients with an Inactivating Defect of the GH-Releasing Hormone (GHRH) Receptor Is Pulsatile: Evidence for a Role for Non-GHRH Inputs into the Generation of GH Pulses. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2459-2464.	1.8	94
249	Additional Beneficial Effects of Alendronate in Growth Hormone (GH)-Deficient Adults with Osteoporosis Receiving Long-Term Recombinant Human GH Replacement Therapy: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3079-3085.	1.8	25
250	Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels. <i>Clinical Endocrinology</i> , 2000, 53, 321-327.	1.2	63
251	Measurement of interleukin 10 in bronchoalveolar lavage from preterm ventilated infants. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2000, 82, 156F-159.	1.4	48
252	Ten-Year Follow-Up Results of Transsphenoidal Microsurgery in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4596-4602.	1.8	164

#	ARTICLE	IF	CITATIONS
253	Long-Term Follow-Up Results of Postoperative Radiotherapy in 36 Patients with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2476-2482.	1.8	155
254	The use of e-REC for capturing the occurrence of covid-19 infections in people with rare endocrine conditions. Endocrine Abstracts, 0, , .	0.0	0
255	Long-Term Follow-Up Results of Postoperative Radiotherapy in 36 Patients with Acromegaly. , 0, .		49
256	Additional Beneficial Effects of Alendronate in Growth Hormone (GH)-Deficient Adults with Osteoporosis Receiving Long-Term Recombinant Human GH Replacement Therapy: A Randomized Controlled Trial. , 0, .		10
257	Longitudinal assessment of response to treatment with oral octreotide capsules in patients with acromegaly: post-hoc analysis of a phase 3 trial. Endocrine Abstracts, 0, , .	0.0	4
258	Progression of vertebral fractures in long-term controlled acromegaly: A 9-year follow-up study. Endocrine Abstracts, 0, , .	0.0	2
259	Opioids and their endocrine effects: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 0, , .	1.8	0
260	Opioids and their endocrine effects: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 0, , .	1.8	0
261	Costs and Its Determinants in Pituitary Tumour Surgery. Frontiers in Endocrinology, 0, 13, .	1.5	1